The role of gamma-synuclein in cocaine-induced behaviour in rats

European Journal of Neuroscience

Volumn 27, Issue 11, 2008, Pages 2938-2951

  Boyer, Frederic ^a   Dreyer, Jean Luc ^a  

^a UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Addiction; Cocaine; Drugs of abuse; Gamma synuclein; In vivo gene transfer; Lentivirus; siRNA

Indexed keywords

COCAINE; COMPLEMENTARY DNA; DOPAMINE TRANSPORTER; DOXYCYCLINE; GAMMA SYNUCLEIN; LENTIVIRUS VECTOR; MESSENGER RNA; PUTATIVE NEUROTRANSMITTER; SMALL INTERFERING RNA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG PROTEIN BINDING; FLUORESCENCE MICROSCOPY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NONHUMAN; NUCLEUS ACCUMBENS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REWARD; STEREOTAXIC SURGERY; WESTERN BLOTTING;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CELL LINE; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; DOWN-REGULATION; GAMMA-SYNUCLEIN; GENE SILENCING; GENETIC VECTORS; HUMANS; HYPERKINESIS; LENTIVIRUS; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 45149098993     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2008.06198.x     Document Type: Article

References (63)

1. Abeliovich, A., Schmitz, Y., Farinas, I., Choy-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D. Rosenthal, A. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron, 25, 239 252.
2. Aguilar, R.C. Wendland, B. (2003) Ubiquitin: not just for proteasomes anymore. Curr. Opin. Cell Biol., 15, 184 190.
3. Bahi, A., Boyer, F., Bussard, G. Dreyer, J.L. (2005) Silencing dopamine D3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur J. Neurosci., 21, 3415 3426.
4. Bahi, A., Boyer, F., Gumy, C., Kafri, T. Dreyer, J.L. (2004a) In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioral changes in chronic cocaine administration. Eur J. Neurosci., 20, 3473 3488.
5. Bahi, A., Boyer, F., Kafri, T. Dreyer, J.L. (2004b) CD81-induced behavioral changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur J. Neurosci., 19, 1621 1633.
6. Boyer, F. Dreyer, J.L. (2007) Alpha-synuclein in the nucleus accumbens induces changes in cocaine behavior in rats. Eur J. Neurosci., 26, 2764 2776.
7. Brenz-Verca, M.S., Bahi, A., Boyer, F., Wagner, G.C. Dreyer, J.L. (2003) Distribution of alpha- and gamma-synucleins in the adult rat brain and their modification by high-dose cocaine treatment. Eur. J. Neurosci., 18, 1923 1938.
8. Buchman, V.L., Hunter, H.J., Pinon, L.G., Thompson, J., Privalova, E.M., Ninkina, N.N. Davies, A.M. (1998) Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J. Neurosci., 18, 9335 9341.
9. Cappai, R., Leck, S.L., Tew, D.J., Williamson, N.A., Smith, D.P., Galatis, D., Sharples, R.A., Curtain, C.C., Ali, F.E., Cherny, R.A., Culvenor, J.G., Bottomley, S.P., Masters, C.L., Barnham, K.J., Hill, A.F. (2005) Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J., 19, 1377 1379.
10. Chen, N. Reith, M.E. (2000) Structure and function of the dopamine transporter. Eur. J. Pharmacol., 405, 329 339.
11. Choi, P., Golts, N., Snyder, H., Chong, M., Petrucelli, L. Hardy, J. (2001) Co association of parkin and alpha-synuclein. Neuroreport, 12, 2839 2843.
12. Chung, K.K., Zhang, Y., Lim, K.L., Tanaka, Y., Huang, H., Gao, J., Ross, C.A., Dawson, V.L. Dawson, T.M. (2001) Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med., 7, 1144 1150.
13. Conway, K.A., Rochet, J.C., Bieganski, R.M. Lansbury, P.T. Jr. (2001) Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science, 294, 1346 1349.
14. Daniels, G.M. Amara, S.G. (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J. Biol. Chem., 274, 35794 35801.
15. Ferguson, S.S. (2003) Receptor tyrosine kinase transactivation: fine-tuning synaptic transmission. Trends Neurosci., 26, 119 122.
16. Galvin, J.E., Giasson, B., Hurtig, H.I., Lee, V.M. Trojanowski, J.Q. (2000) Neurodegeneration with brain iron accumulation, type-1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Am. J. Pathol., 157, 361 368.
17. Galvin, J.E., Uryu, K., Lee, V.M. Trojanowski, J.Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl Acad. Sci. USA, 96, 13450 13455.
18. George, J.M. (2001) The synucleins. Gen. Biol., 3, 3002.1 3002. 6 [Review].
19. Hashimoto, M., Rockenstein, E., Mante, M., Mallory, M. Masliah, E. (2001) Beta-synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron, 32, 213 223.
20. Hicke, L. (2001) Protein regulation by mono-ubiquitin. Nat. Rev. Mol. Cell Biol., 2, 195 201.
21. Hicke, L. Dunn, R. (2003) Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Ann. Rev. Cell Dev. Biology, 19, 141 172.
22. Horn, A.S. (1990) Dopamine uptake: a review of progress in the last decade. Prog. Neurobiol., 34, 387 400.
23. Jia, T., Liu, Y.E., Liu, J. Shi, Y.E. (1999) Stimulation of breast cancer invasion and metastasis by synuclein gamma. Cancer Res., 59, 742 747.
24. Jiang, H., Ren, Y., Zhao, J. Feng, J. (2004) Parkin protects human dopaminergic neuroblastoma cells against dopamineinduced apoptosis. Hum. Mol. Genet., 13, 1745 1754.
25. Kim, T.D., Paik, S.R. Yang, C.H. (2002) Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry., 41, 13782 13790.
26. Kuhn, M., Haebig, K., Bonin, M., Ninkina, N., Buchman, V.L., Poths, S. Riess, O. (2007) Whole genome expression analyses of single- and double-knock-out mice implicate partially overlapping functions of alpha- and gamma-synuclein. Neurogenetics, 8, 71 81.
27. Lavedan, C. (1998) The synuclein family. Gen. Res., 8, 871 880.
28. LaVoie, M.J., Ostaszewski, B.L., Weihofen, A., Schlossmacher, M.G. Selkoe, D.J. (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med., 11, 1214 1221.
29. Li, J.Y., Henning-Jensen, P. Dahlstrom, A. (2002) Differential localization of alpha, beta- and gamma-synucleins in the rat CNS. Neuroscience, 113, 463 478.
30. Liang, T., Spence, J., Liu, L., Strother, W.N., Chang, H.W., Ellison, J.A., Lumeng, L., Li, T.K., Foroud, T. Carr, L.G. (2003) alpha-Synuclein maps to a quantitative trait locus for alcohol preference and is differentially expressed in alcoholpreferring and - nonpreferring rats. Proc. Natl Acad. Sci. USA, 100, 4690 4695.
31. Lim, K.L., Chew, K.C., Tan, J.M., Wang, C., Chung, K.K., Zhang, Y., Tanaka, Y., Smith, W., Engelender, S., Ross, C.A., Dawson, V.L. Dawson, T.M. (2005) Parkin mediates nonclassical, proteasomalindependent ubiquitination of synphilin-1: implications for Lewy body formation. J. Neurosci., 25, 2002 2009.
32. LoBianco, C., Ridet, J.L., Schneider, B.L., Deglon, N. Aebischer, P. (2002) Alpha-synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 99, 10813 10818.
33. Maggos, C.E., Spangler, R., Zhou, Y., Schlussman, S.D., Ho, A. Kreek, M.J. (1998) Quantitation of dopamine transporter mrna in the rat brain: mapping, effects of binge cocaine administration and withdrawal. Synapse, 26, 55 61.
34. Mash, D.C., Ouyang, Q., Pablo, J., Basile, M., Izenwasser, S., Lieberman, A. Perrin, R.J. (2003) Cocaine abusers have an overexpression of alpha-synuclein in dopamine neurons. J. Neurosci., 23, 2564 2571.
35. Maurage, C.A., Ruchoux, M.M., de Vos, R., Surguchov, A. Destee, A. (2003) Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann. Neurol., 54, 542 547.
36. Melikian, H.E. Buckley, K.M. (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J. Neurosci., 19, 7699 7710.
37. Mosharov, E.V., Staal, R.G., Bove, J., Prou, D., Hananiya, A., Markov, D., Poulsen, N., Larsen, K.E., Moore, C.M., Troyer, M.D., Edwards, R.H., Przedborski, S. Sulzer, D. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci., 26, 9304 9311.
38. Moszczynska, A., Saleh, J., Zhang, H., Vukusic, B., Lee, F.J.S. Liu, F. (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J. Mol. Neurosci., 32, 217 227.
39. Murphy, D.D., Rueter, S.M., Trojanowski, J.Q. Lee, V.M. (2000) Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci., 20, 3214 3220.
40. Oluwatosin-Chigbu, Y., Robbins, A., Scott, C.W., Arriza, J.L., Reid, J.D. Zysk, J.R. (2003) Parkin suppresses wild-type alphasynuclein-induced toxicity in SHSY-5Y cells. Biochem. Biophys. Res. Commun., 309, 679 684.
41. Paxinos, G. Watson, C. (1998) The Rat Brain in Stereotactic Coordinates. Academic, New York.
42. Perez, R.G., Waymire, J.C., Lin, E., Liu, J.J., Guo, F. Zigmond, M.J. (2002) A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 22, 3090 3099.
43. Petrucelli, L., O'Farrell, C., Lockhart, P.J., Baptista, M., Kehoe, K., Vink, L., Choi, P., Wolozin, B., Farrer, M., Hardy, J. Cookson, M.R. (2002) Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron, 36, 1007 1019.
44. Pickart, C.M. (2000) Ubiquitin in chains. Trends Biochem. Sci., 25, 544 548.
45. Pinhasov, A., Ilyin, S.E., Crooke, J., Amato, F.A., Vaidya, A.H., Rosenthal, D., Brenneman, D.E. Malatynska, E. (2005) Different levels of gamma-synuclein mRNA in the cerebral cortex of dominant, neutral and submissive rats selected in the competition test. Genes, Brain Behav., 4, 60 64.
46. Pristupa, Z.B., McConkey, F., Liu, F., Man, H.Y., Lee, F.J., Wang, Y.T. Niznik, H.B. (1998) Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse, 30, 79 87.
47. Qin, A., Ouyang, Q., Pablo, J. Mash, D.C. (2005) Cocaine abuse elevates alpha-synuclein and dopamine transporter levels in human striatum. Neuroreport, 16, 1489 1493.
48. Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K.S. Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 263 269.
49. Sidhu, A., Wersinger, C. Vernier, P. (2004a) alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett., 565, 1 5.
50. Sidhu, A., Wersinger, C., Vernier, P. (2004b) Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J., 18, 637 647.
51. Surgucheva, I., McMahan, B., Ahmed, F., Tomarev, S., Wax, M.B. Surguchov, A. (2002) Synucleins in glaucoma: implication of gamma-synuclein in glaucomatous alterations in the optic nerve. J. Neurosci. Res., 68, 97 106.
52. Surgucheva, I.G., Sivak, J.M., Fini, M.E., Palazzo, R.E. Surguchov, A.P. (2003) Effect of gamma-synuclein overexpression on matrix metalloproteinases in retinoblastoma Y79 cells. Arch. Biochem. Biophys., 410, 167 176.
53. Surguchov, A., McMahan, B., Masliah, E. Surgucheva, I. (2001b) Synucleins in ocular tissues. J. Neurosci. Res., 65, 68 77.
54. Surguchov, A., Palazzo, R.E. Surgucheva, I. (2001a) Gamma synuclein: subcellular localization in neuronal and non-neuronal cells and effect on signal transduction. Cell Motil Cytoskeleton, 49, 218 228.
55. Uversky, Z.N., Li, J., Souillac, P., Millett, I.S., Doniach, S., Jakes, R., Goedert, M. Fink, A.L. (2002) Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem., 277, 11970 11978.
56. Wang, Y.L., Takeda, A., Osaka, H., Hara, Y., Furuta, A., Setsuie, R., Sun, Y.J., Kwon, J., Sato, Y., Sakurai, M., Noda, M., Yoshikawa, Y. Wada, K. (2004a) Accumulation of beta- and gamma-synucleins in the ubiquitin carboxyl-terminal hydrolase L1-deficient gad mouse. Brain Res., 1019, 1 9.
57. Wersinger, C., Prou, D., Vernier, P. Sidhu, A. (2003a) Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J., 17, 2151 2153.
58. Wersinger, C., Prou, D., Vernier, P., Niznik, H.B. Sidhu, A. (2003b) Mutations in the lipid-binding domain of alpha-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity. Mol. Cell Neurosci., 24, 91 105.
59. Wersinger, C., Rusnak, M. Sidhu, A. (2006) Modulation of the trafficking of the human serotonin transporter by human alpha-synuclein. Eur. J. Neurosci., 24, 55 64.
60. Wersinger, C. Sidhu, A. (2003) Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett., 340, 189 192.
61. Wersinger, C. Sidhu, A. (2005) Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter. Biochemistry, 44, 13612 13624.
62. Xu, J., Kao, S.Y., Lee, F.J., Song, W., Jin, L.W. Yankner, B.A. (2002) Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med., 8, 600 606.
63. Yamada, M., Mizuno, Y. Mochizuki, H. (2005) Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. Human Gene Ther., 16, 262 270.